Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Gliosarcoma × Immunotherapy, Adoptive × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 CNS 1

Conditions

Lymphoma, Mantle-Cell 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia, Myeloid, Acute 2 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neuroblastoma 1 Multiple Myeloma 1 Melanoma 1 Lymphoma, T-Cell 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lymphoma 1 Leukemia, Lymphoid 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Gliosarcoma 1 Glioblastoma 1 Central Nervous System Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Burkitt Lymphoma 1 Brain Neoplasms 1

Interventions

Temozolomide 48 Bevacizumab 31 Radiotherapy 24 Radiation 11 Erlotinib Hydrochloride 11 Radiotherapy, Intensity-Modulated 7 Radiotherapy, Conformal 7 Irinotecan 6 Vorinostat 5 Immunoglobulin G 4 Disulfides 4 Carmustine 4 plerixafor 3 carmustine, poliferprosan 20 drug combination 3 Sorafenib 3 Sirolimus 3 Radiosurgery 3 Magnetic Resonance Spectroscopy 3 Everolimus 3 Dasatinib 3 Bortezomib 3 veliparib 2 vandetanib 2 temsirolimus 2 tandutinib 2 sargramostim 2 pazopanib 2 ferric pyrophosphate 2 cediranib 2 Topotecan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02664363 2023-02-17

ExCeL

Duke University

Phase 1 Terminated

3 enrolled 8 charts

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡